TripTerest - Board

Follow

Denis Katz Medical Affairs

Salience Clinical Consulting

The second sponsor, smaller and working in a rare neuromuscular indication, did something different. Before locking their pivotal trial design, they brought the proposed endpoint, population, and statistical plan to FDA in a Type B meeting and asked directly whether a functional outcome measure under development would be considered adequately validated in that population.

Login
Login

0 repins 0 comments 0 likes

Back to Top